121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
Titel:
121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
Auteur:
Yang, Y. Pan, J. Wang, H. Qu, S. Chen, N. Chen, X. Sun, Y. He, X. Hu, C. Lin, L. Yu, Q. Wang, S. Wang, G. Lei, F. Wen, J. Yang, K. Lin, Z. Wu, Y. Fang, W. Zhang, L.